Letters To The Editor
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2014; 20(39): 14515-14516
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14515
AIMS65: A promising upper gastrointestinal bleeding risk score but further validation required
Ray Boyapati, Avik Majumdar, Marcus Robertson
Ray Boyapati, Avik Majumdar, Marcus Robertson, Department of Gastroenterology and Liver Transplant, Austin Hospital, Heidelberg VIC 3084, Australia
Author contributions: Boyapati R drafted the work; Majumdar A and Robertson M revised and edited the work; all authors were involved in designing the work and giving final approval for the published version.
Correspondence to: Ray Boyapati, MBBS, Department of Gastroenterology and Liver Transplant, Austin Hospital, 145 Studley Road, Heidelberg VIC 3084, Australia. ray.boyapati@yahoo.com
Telephone: +61-3-94965353 Fax: +61-3-94963487
Received: March 24, 2014
Revised: April 23, 2014
Accepted: June 12, 2014
Published online: October 21, 2014
Processing time: 210 Days and 7.3 Hours
Abstract

A novel upper gastrointestinal bleeding risk stratification score (AIMS65) has recently been developed and validated. It has advantages over existing risk scores including being easy to remember and lack of subjectivity in calculation. We comment on a recent study that has cast doubt on the applicability of AIMS65 in the peptic ulcer disease population. Although promising, further studies are required to evaluate the validity of AIMS65 in various populations.

Keywords: Gastrointestinal haemorrhage; AIMS65; Endoscopy; Prognosis; Hemostasis; Gastrointestinal bleeding

Core tip: A novel upper gastrointestinal bleeding risk stratification score (AIMS65) has recently been developed and validated. It has advantages over existing risk scores including being easy to remember and lack of subjectivity in calculation. We comment on a recent study that has cast doubt on the applicability of AIMS65 in the peptic ulcer disease population. Although promising, further studies are required to evaluate the validity of AIMS65 in various populations.